NCT00238121View on ClinicalTrials.gov

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Recurrent Uterine SarcomaStage III Uterine SarcomaStage IV Uterine SarcomaUterine Carcinosarcoma
Interventions
DRUG

sorafenib tosylate

Given orally

Trial Locations (7)

60702

Central Illinois Hematology Oncology Center, Springfield

62526

Decatur Memorial Hospital, Decatur

91010

City of Hope Medical Center, Duarte

90033-0804

University of Southern California, Los Angeles

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00238121 - Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer | Biotech Hunter | Biotech Hunter